Clinical Trial Detail

NCT ID NCT01708161
Title A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis|Novartis Pharmaceuticals|Amgen
Indications

Advanced Solid Tumor

Therapies

Alpelisib + Ganitumab

Age Groups: adult

Additional content available in CKB BOOST